BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 14678966)

  • 1. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
    Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
    Ikenoue T; Kanai F; Hikiba Y; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Asaoka Y; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Mol Carcinog; 2005 May; 43(1):59-63. PubMed ID: 15791648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
    Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
    Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
    Emuss V; Garnett M; Mason C; Marais R
    Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and role of Raf-1/B-Raf heterodimerization.
    Rushworth LK; Hindley AD; O'Neill E; Kolch W
    Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
    Garnett MJ; Rana S; Paterson H; Barford D; Marais R
    Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2).
    Koong AC; Chen EY; Mivechi NF; Denko NC; Stambrook P; Giaccia AJ
    Cancer Res; 1994 Oct; 54(20):5273-9. PubMed ID: 7923153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
    Arthan D; Hong SK; Park JI
    Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.
    Zhang BH; Guan KL
    EMBO J; 2000 Oct; 19(20):5429-39. PubMed ID: 11032810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
    Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
    Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.